For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane to stabilize energy production and reduce oxidative stress. It received FDA accelerated approval in 2025 for Barth syndrome, making it the first treatment ever approved for this cardiolipin disorder. Multiple Phase 2 trials are underway for heart failure, renal disease, and age-related conditions.
SS-31 (elamipretide) received FDA accelerated approval in 2025 for Barth syndrome specifically, under the brand name ELAMINE. This approval is based on the TAZPOWER trial data and is limited to Barth syndrome. All other indications described in this profile are investigational and remain in clinical or preclinical development. For all non-Barth applications, SS-31 is a research compound requiring IND filing for human use in the United States.
The recurring pattern across SS-31 clinical trials is important context: functional endpoints (walk distance, quality of life) have shown consistent positive signals, while structural endpoints (LV volumes, infarct size, geographic atrophy area) have generally been missed. This pattern shapes how the evidence should be interpreted across all indications.
SS-31 (elamipretide) is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, discovered fortuitously by Szeto and Schiller while studying opioid receptors. It belongs to the SS (Szeto-Schiller) peptide family, a class of novel mitochondria-targeting antioxidants designed around alternating aromatic residues and basic amino acids that allow electrostatic targeting of the inner mitochondrial membrane.
Unlike most research peptides, SS-31 has achieved regulatory validation: in 2025, the FDA granted elamipretide accelerated approval for Barth syndrome, making it the first treatment ever approved for this otherwise untreatable rare genetic condition. This regulatory milestone is significant not only for Barth syndrome patients but as proof-of-concept that SS-31's mitochondrial mechanism produces clinically meaningful outcomes in humans with verified cardiolipin pathway dysfunction.
SS-31 entered clinical development in 2010 with Stealth Biotherapeutics under the clinical names Elamipretide and Bendavia. Its mechanism is fundamentally different from all other peptides reviewed in this series: while Tα1 works on immune cells and BPC-157 works on vascular and tissue repair pathways, SS-31 works inside the mitochondria, stabilizing the physical architecture of the inner mitochondrial membrane to restore energy production and reduce oxidative damage at the cellular power source level.
SS-31's mechanism is unique among all peptides in this research series: it works inside the mitochondria rather than at cell surface receptors. The target is cardiolipin, a specialized phospholipid found exclusively in the inner mitochondrial membrane that is essential for maintaining the membrane's folded cristae structure, anchoring the electron transport chain complexes in their functional positions, and enabling efficient ATP synthesis.
SS-31 reaches cardiolipin by electrostatic attraction: the peptide carries positive charges (from its D-Arg and Lys residues) that are attracted to the highly negative charge of cardiolipin in the inner mitochondrial membrane. Once bound to cardiolipin, SS-31 physically stabilizes the membrane structure, preventing the cristae unfolding that occurs under conditions of oxidative stress or cardiolipin deficiency. This structural stabilization has cascading functional benefits: better-organized electron transport chain, reduced electron leakage and ROS production, improved ADP uptake via the adenine nucleotide translocator (ANT), and ultimately more efficient ATP synthesis.
A key property is that SS-31 appears to have no effect on healthy mitochondria, selectively targeting dysfunctional mitochondria where cardiolipin is oxidized or structurally disrupted. This selectivity for pathological states is unusual and explains the consistently clean safety profile seen across clinical trials.
SS-31 binds cardiolipin in the inner mitochondrial membrane via electrostatic attraction, stabilizing the cristae structure that is essential for energy production. It reduces ROS (free radical) generation by preventing electron leakage from the transport chain, and improves ADP-to-ATP conversion efficiency. The Dmt residue actively scavenges oxygen radicals. The net result is restored cellular energy production and reduced oxidative damage in mitochondria-stressed tissues.
Barth syndrome is a rare X-linked genetic disorder caused by mutations in the Tafazzin (TAZ) enzyme involved in cardiolipin remodeling. The result is abnormal cardiolipin composition throughout all mitochondria, causing severe cardiomyopathy, skeletal myopathy, growth retardation, neutropenia, and high mortality, with no disease-specific treatment existing prior to 2025.
The TAZPOWER trial directly targeted this cardiolipin defect. Phase 2/3 data demonstrated that 48 weeks of elamipretide treatment produced significant improvement in performance on the 6-Minute Walk Test (6MWT) and the BTHS Symptom Assessment Scale (BTHS-SA), as well as measurable improvement in cardiac physiology. The open-label extension confirmed durability of response at 168 weeks (over 3 years).
The FDA granted accelerated approval in 2025, making elamipretide (marketed as ELAMINE) the first-ever treatment for Barth syndrome. Accelerated approval was based on the 6MWT and symptom improvement data, with post-approval confirmatory trials required to verify long-term clinical benefit. This regulatory milestone directly validates the cardiolipin mechanism in humans.
The strongest and most definitively validated clinical application for SS-31. The TAZPOWER data directly confirmed the cardiolipin mechanism in human disease, produced statistically significant improvements on pre-specified endpoints, and resulted in the first FDA accelerated approval for an otherwise untreatable rare disease. This represents the proof-of-concept that SS-31's mitochondrial mechanism produces real clinical outcomes, a foundation that supports the biological plausibility of its other applications.
The PROGRESS-HF Phase 2 trial enrolled 71 patients with heart failure with reduced ejection fraction (HFrEF, LVEF less than 40%) in a double-blind randomized controlled design. The primary structural endpoint, change in left ventricular end systolic volume, was not significantly altered by SS-31 treatment for 28 days. Similarly, in the PCI/myocardial infarction trial, SS-31 was not associated with a decrease in myocardial infarct size, though congestive heart failure events within 24 hours of intervention trended toward reduction.
The more compelling data emerged from the HFpEF arm of PROGRESS-HF, which showed significant improvements in 6-minute walk distance and patient-reported quality of life. This is mechanistically notable because HFpEF, heart failure with preserved ejection fraction, is substantially driven by mitochondrial dysfunction in cardiac muscle rather than gross structural remodeling, making it a theoretically better fit for SS-31's mechanism than HFrEF.
The Chatfield et al. (2019) study in failing human cardiac tissue (ex vivo) provided direct mechanistic confirmation that elamipretide improves mitochondrial function specifically in failing human hearts, bridging the preclinical mechanism to human cardiac tissue.
Mixed results: structurally categorized as a failure, functionally more interesting. The divergence between negative structural endpoints (LV volumes, infarct size) and positive functional outcomes (walk distance, quality of life) is clinically meaningful and mechanistically consistent: SS-31 appears to improve cellular energetics and patient experience without reversing gross cardiac architectural remodeling. This suggests that future trials may need to use functional and quality-of-life endpoints as primaries rather than volumetric imaging endpoints, and that HFpEF may be a better-matched indication than HFrEF for SS-31's mechanism.
The MMPOWER Phase I/II trial enrolled 36 participants with genetically confirmed primary mitochondrial myopathy (PMM) and provided Class I evidence that IV elamipretide is well tolerated and improves exercise performance in a dose-dependent manner compared to placebo. The primary efficacy measure, change in 6-minute walk distance after 5 days, showed meaningful functional improvement at the optimal dose.
This positive Phase I/II signal led to the Phase 3 MMPOWER-3 trial using 40 mg/day subcutaneously. The larger trial did not meet its primary endpoints. This represents a pattern, dose-dependent Phase I/II benefit that fails to scale to Phase 3 significance, that recurs across SS-31's clinical development and is likely explained by a combination of endpoint selection challenges, heterogeneity within the PMM patient population, and the difficulty of powering rare disease trials.
Encouraging Phase I/II dose-dependent functional improvement was not replicated at primary endpoint level in Phase 3. This outcome, consistent across multiple SS-31 indications, suggests that the compound may produce genuine biological benefit that existing clinical trial endpoints and designs are not optimally capturing. Endpoint selection (functional measures vs. static structural measures) and patient stratification by mitochondrial dysfunction severity are likely the critical variables for future trial design.
SS-31 has a noteworthy pharmacokinetic property: among all organs studied, the kidneys show the highest concentration of SS-31 after administration, and the compound is completely excreted renally. This natural organ-level accumulation creates a built-in pharmacological advantage for renal applications that is not present in other indications.
The ReCLAIM Phase 2a trial examined SS-31 administered during stent placement in patients with atherosclerotic renal artery stenosis. Results showed that SS-31 administration was associated with improved kidney blood flow and function three months post-procedure, one of SS-31's more convincing human signals outside of Barth syndrome. The mechanism is consistent: renal ischemia-reperfusion during stenting generates oxidative stress and mitochondrial injury that SS-31 directly counteracts.
Preclinical data across multiple AKI and ischemia-reperfusion models is robustly positive. The renal accumulation explains the strong and consistent preclinical performance.
The ReCLAIM renal artery stenosis trial produced one of SS-31's more convincing non-Barth human signals. The combination of strong preclinical data, natural pharmacokinetic renal accumulation, and a positive Phase 2a human signal makes the kidney one of SS-31's most translatable applications. Larger Phase 2/3 renal protection trials are scientifically well-justified.
The ReCLAIM AMD trial examined SS-31 in dry AMD (geographic atrophy), targeting the mitochondria-rich photoreceptor layer of the retina, the ellipsoid zone (EZ), which is the layer thought to correspond to photoreceptor mitochondrial density. The primary endpoints (changes in low luminance best-corrected visual acuity and geographic atrophy area) were not met.
However, a meaningful secondary finding emerged: elamipretide was associated with a statistically significant slowing of progressive ellipsoid zone (EZ) degradation, the rate at which the mitochondria-rich photoreceptor layer deteriorates. EZ integrity is an established predictor of progressive vision loss, and slowing its degradation may correlate with reduced progressive photoreceptor degeneration even when gross atrophy area is unchanged in the short term.
A nuanced result: primary endpoints missed, but a mechanistically coherent secondary biomarker was positively affected. This pattern is consistent with SS-31's profile across multiple indications: it appears to slow mitochondrial deterioration rather than reverse established structural damage, which may require different trial designs (longer duration, progression-rate endpoints rather than static cross-sectional measures) to capture the true clinical benefit. The EZ finding is hypothesis-generating for future AMD trial design.
Prolonged treatment with SS-31 in aged animal models reversed energetic deficits in aged mitochondria and improved resting and dynamic skeletal muscle function and redox homeostasis. The gastrocnemius in age+SS-31 mice was more fatigue resistant with significantly greater mass compared to aged controls, contributing to a significant increase in treadmill endurance compared to both pretreatment and untreated control values.
Pharaoh et al. (2023) provided the most precise mechanistic characterization: elamipretide treatment increased ADP sensitivity in old muscle mitochondria by increasing ADP uptake through the adenine nucleotide translocator (ANT), the protein that exchanges ADP for ATP across the inner mitochondrial membrane. ANT function declines with aging due to increased S-glutathionylation (oxidative modification), and SS-31 reversed this. Treatment decreased protein S-glutathionylation including of ANT directly, restoring its transport function and thereby improving the muscle's ability to produce ATP on demand during exercise.
Among the most compelling mechanistic data for any anti-aging peptide in current research. The Pharaoh et al. (2023) findings are particularly significant: they directly connect the molecular mechanism (ANT de-glutathionylation, improved ADP transport, more ATP produced per demand signal) to a measurable functional outcome (muscle force and endurance recovery in aged tissue). This is the level of mechanistic resolution that validates a therapeutic target for human trials. Sarcopenia RCTs in aged humans are the logical and urgently needed next step.
SS-31 provides protection against secondary brain injury following traumatic brain injury, stroke, and neurodegenerative pathology in preclinical models, reducing DNA damage and neuronal apoptosis. The mechanisms are consistent with systemic action: mitochondria are essential for neuronal energy supply and synaptic function, and mitochondrial dysfunction is well-established in Alzheimer's disease, Parkinson's disease, and TBI secondary injury cascades.
Preclinical data across cognitive impairment, TBI, and stroke models are generally positive. However, these effects have not been confirmed in humans, and the Alzheimer's Drug Discovery Foundation's Cognitive Vitality review (which applies rigorous evidence standards) rates the human evidence base as insufficient for clinical recommendations.
Mechanistically compelling, mitochondrial dysfunction is robustly established in neurodegeneration, but the human evidence is entirely absent. This is currently a preclinical-only area. The most significant translational hurdle is blood-brain barrier penetration: SS-31's positive charge and relatively small size theoretically enable some CNS penetration, but this has not been formally characterized in humans with pharmacokinetic studies. Until BBB penetration is confirmed in humans, the neurodegeneration applications remain theoretical despite strong preclinical data.
Preclinical studies showed strong protection with SS-31 pretreatment: significantly reduced myocardial lipid peroxidation and infarct size in rats undergoing ischemia-reperfusion. The translation to humans in the Gibson et al. Phase 2a trial was partial. Infarct size reduction was not achieved as a primary endpoint, but early congestive heart failure events in the 24 hours following PCI trended toward reduction in the SS-31 group.
The timing of administration appears critical to efficacy in ischemia-reperfusion: preclinical models with pretreatment before ischemia consistently show stronger effects than post-ischemia administration. The clinical trial design (peri-procedural administration during PCI) may not have optimally replicated the most protective preclinical protocol.
Strong preclinical signal, partially translated in humans. The partial translation, protecting against early HF events but not infarct size, may reflect timing and endpoint selection rather than mechanism failure. Future trials may need to test longer pretreatment windows or focus on functional endpoints rather than infarct size imaging.
SS-31 exhibits broad protective effects in preclinical models of metabolic disease including cardiac, neurological, respiratory, retinal, kidney, and aging-related conditions as well as sepsis and diabetes. In diabetic nephropathy specifically, SS-31 reduces oxidative stress generated by hyperglycemia-driven mitochondrial dysfunction in renal tubular cells, modulates CD36 lipid receptor expression, and measurably improves renal function markers.
Given SS-31's natural pharmacokinetic accumulation in the kidney and its established protection against renal ischemia in human trials, diabetic nephropathy represents a mechanistically well-aligned and clinically high-priority target. The global burden of diabetic kidney disease is enormous and current treatments remain inadequate.
Promising preclinical data with a strong mechanistic rationale and a favorable pharmacokinetic advantage. No dedicated human trial exists yet, but this is one of the most scientifically justifiable next clinical development targets given the convergence of renal accumulation, established mechanistic validation in renal disease (ReCLAIM trial), and the huge unmet clinical need in diabetic nephropathy.
40mg is FDA-approved for Barth syndrome. Clinical trial also tested 4mg. Community typically uses 1-5mg daily.
SS-31 has the most robust human dosing data of any non-approved peptide in this series, and the only FDA-approved dosing protocol (40 mg/day SubQ for Barth syndrome). For research use outside Barth syndrome, all dosing is investigational and IND filing is required for human use in the United States. The D-Arg residue (D-amino acid) is critical to function: confirm D-configuration in CoA, as L-Arg substitution significantly alters the electrostatic targeting mechanism. Dmt (2',6'-dimethyltyrosine) must also be confirmed: standard Tyr substitution eliminates radical scavenging activity. Research-grade standards: HPLC purity 98% or above, mass spec confirmation of molecular weight (approximately 640 Da), chiral purity confirmation, endotoxin below 1 EU/mg for injectable use.
SS-31 vs. Thymosin Alpha-1: These compounds are often compared but the comparison is misleading. They are mechanistically unrelated. Tα1 modulates T-cell immune responses through TLR signaling; SS-31 stabilizes mitochondrial membrane architecture through cardiolipin binding. They operate in entirely different biological domains: immune system vs. cellular energy infrastructure. SS-31 has one FDA accelerated approval (Barth syndrome, 2025); Tα1 holds approvals in 35+ countries for hepatitis and immune enhancement but has no US FDA approval.
SS-31 vs. MOTS-c (Mitochondrial Comparison): Both are mitochondrial peptides but at different levels. MOTS-c is a mitochondrial-derived peptide that, when mitochondrial stress is sensed, translocates to the nucleus and activates AMPK and folate-cycle genes to reprogram metabolism. SS-31 works at the IMM structural level, stabilizing cardiolipin and restoring physical mitochondrial architecture. These are complementary rather than competing mechanisms: MOTS-c is metabolic signaling; SS-31 is structural repair. Mechanistic complementarity makes them a scientifically rational co-administration candidate for aging and sarcopenia research.
SS-31 has a well-documented safety profile from multiple clinical trials including a 168-week (over 3-year) open-label extension of the TAZPOWER trial, the longest continuous human exposure data for any compound in this research series. Across all clinical studies, no clinically significant differences in vital signs, laboratory values, physical examination findings, or ECG-measured parameters have been identified.
The primary adverse effects are injection-site reactions, which are common (erythema 57%, pruritus 47%) but mild and transient. These are expected with SubQ injection of any peptide and do not represent systemic toxicity. The absence of organ toxicity signals across extended use is a meaningful safety endorsement given the compound's mechanism: one might theoretically worry that globally altering mitochondrial function could have unintended systemic effects, but the clinical data consistently contradicts this concern.
No absolute contraindications have been established for non-Barth syndrome research applications. Known cautions: injection site reactions are common, proper SubQ technique and site rotation minimizes impact. No significant drug interactions documented. Pregnancy: no safety data, standard precautionary avoidance. The general conclusion from the clinical trial program is that benefits outweigh risks in patients with mitochondrial dysfunction-related conditions.
SS-31 is mechanistically the most precise and well-characterized peptide in this research series. Its target (cardiolipin), its binding mechanism (electrostatic IMM targeting), and its downstream effects (cristae stabilization, ANT restoration, ROS scavenging) are all understood at the molecular level and confirmed in human tissue. Its FDA accelerated approval for Barth syndrome is the strongest regulatory validation of any compound reviewed here.
The clinical development challenge is a recurring theme: functional benefits in humans are real but are consistently failing to translate into statistically significant improvements on structural primary endpoints in Phase 3. The field likely needs to redesign trials around functional and progression-rate endpoints, and to match indications more precisely to the severity of mitochondrial dysfunction.
Sarcopenia and diabetic nephropathy may be better near-term targets than the complex heart failure population. Both have strong mechanistic rationale, favorable pharmacokinetics (renal accumulation), and the lessons from prior trials to guide endpoint design.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use